Request for Proposal
new-logo

EVDAS Monitoring for Signal Detection: What Commission Implementing Regulation (EU) 2025/1466 Means for Marketing Authorization Holders (MAHs)

Key implementation timelines:

  • 22 July 2025 – Regulation published in the Official Journal of the European Union
  • 12 August 2025 – Core provisions, including EVDAS monitoring for signal detection, start to apply
  • 12 February 2026 – Full regulation becomes applicable

EVDAS is the EudraVigilance Data Analysis System, an analytical tool used by the European Medicines Agency (EMA) to support pharmacovigilance and identify potential safety concerns with medicines in the EU. It analyses safety reports from the EudraVigilance database to detect potential safety signals, and EMA utilizes this system to support national competent authorities and marketing authorization holders in monitoring and evaluating drugs. 

COMMISSION IMPLEMENTING REGULATION (EU) 2025/1466 of 22 July 2025, which came into effect from the twentieth day following the publication of the revised IR 520/2012 i.e., from 12 August 2025.

Under the previous framework (Implementing Regulation (EU) 520/2012), only specific active substances were subject to mandatory EudraVigilance (EV) monitoring. The new regulation closes that chapter: the pilot list approach is abolished, and EVDAS becomes a compulsory data source for signal detection for every MAH operating in Europe and use it as an additional source of safety information to support their processes and enhance signals detected through other sources e.g., internal databases, literature, spontaneous reports.

An update to the Good Pharmacovigilance Practices (GVP) IX is scheduled to be implemented in Q2 2026, in alignment with the forthcoming requirements. However, MAH signal management process should reflect these changes with immediate effect.

Under the previous framework, MAHs were expected to consult EVDAS data primarily after the identification of a potential safety signal, using it as a confirmatory or supportive data source. With the introduction of Implementing Regulation (EU) 2025/1466, this approach fundamentally changes. EVDAS data must now be actively monitored throughout all stages of the signal management process, from early signal detection through validation, assessment, and prioritisation.

For MAHs, the time to act and ensure compliance is immediate:

MAHs with EU products authorised in Northern Ireland (NI) should monitor EudraVigilance (EVDAS), even if they are not authorised in an EU/EEA Member State.

MAH need to ensure they have trained personnel (safety physicians), access to EV analyses, and robust procedures to manage increased workload.

MAHs now need to mandatory review EVDAS data as part of their signal detection activities, of course it could be risk-based approach (based on product type, maturity of product, ongoing signal/risk etc.). This means, SOP should be accustomed to the approach.

Update their signal management standard operating procedures, signal detection templates, contracts/agreements and Pharmacovigilance System Master File (PSMF).

Ensure that all pharmacovigilance personnel receive appropriate training.

COD’s Capabilities in Facilitating MAH Compliance and Operations:

  1. COD’s highly experienced signal management team already supports several MAHs globally, enabling companies to align their signal management processes with established industry best practices.
  2. Support MAHs in updating their signal management SOPs to ensure alignment with the requirements of this Implementing Regulation.
  3. Support MAHs in performing end-to-end signal management activities in line with the revised requirements, thereby strengthening preparedness for Regulatory Authority inspections
  4. In the generation of various EVDAS line listings and their evaluation as part of the signal management process.
  5. If signal management activities are outsourced to a subcontractor, COD can assist in performing audits to ensure compliance and quality oversight.
  6. MAHs encountering challenges in aligning their signal management processes with the requirements of the new Implementing Regulation may seek support from COD.
Contact Us!

Conclusion:

The introduction of Commission Implementing Regulation (EU) 2025/1466 represents a significant advancement in the EU pharmacovigilance framework. By mandating EVDAS monitoring for all MAHs, the regulation strengthens the harmonisation of vigilance practices and enhances the early identification of emerging safety concerns.